COVID-19 Pfizer Information

X

Thanks for finding us at WCLC 2022

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases


Thanks for finding us at WCLC 2022

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases

Upcoming Opportunities to Connect

Symposium

Session Title: Is it time to raise the bar for ALK+ NSCLC Patients?
Location: Hall C2, Messe Wien Exhibition & Congress Center
Date and Time: August 6, 2022 14:30 - 15:30 CET

Add To Calendar


Poster Presentations

Presentation Title: Crizotinib in ROS1+ NSCLC: Long-term OS analysis in patients with brain metastases included in the phase II METROS trial
Location: All E-Posters will be displayed on a 60-inch digital screen on both days of the conference
Date and Time: August 7-8, 2022 09:45 – 18:00 CET

Add To Calendar

Presentation Title: Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Location: All E-Posters will be displayed on a 60-inch digital screen on both days of the conference
Date and Time: August 7-8, 2022 09:45 – 18:00 CET

Add To Calendar

Presentation Title: A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
Location: All E-Posters will be displayed on a 60-inch digital screen on both days of the conference
Date and Time: August 7-8, 2022 09:45 – 18:00 CET

Add To Calendar

Presentation Title: Lorlatinib for ALK+ NSCLC patients pretreated with second-generation ALK inhibitors: Canadian real-world experience
Location: All E-Posters will be displayed on a 60-inch digital screen on both days of the conference
Date and Time: August 7-8, 2022 09:45 – 18:00 CET

Add To Calendar

Oral Presentations

Presentation Title: Avelumab vs Chemotherapy for First-Line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis From JAVELIN Lung 100
Location: Strauss 1/2
Date and Time: Tuesday, August 9, 2022 14:30 - 15:30 CET

Add To Calendar

Connect with Pfizer

Please fill out the form below. A member from the team will respond accordingly.

By providing your email address, you agree to receive an email response from Pfizer to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.

All fields marked with an asterisk ( *) are required.

Thank you for
contacting Pfizer.

A team member will respond to your inquiry.

Highlights From Your Congress

View MoreClose

Discover the Oncology Development Program and Clinical Trials

Tile-3
View More
Tile-3
View More

View More

View More
View MoreClose

Is it time to raise the bar for ALK+ NSCLC Patients?

Tile-3
View More
Tile-3
View More

What’s Of Interest

View MoreClose

Patient Education for HCPs

Tile-3
View More
View MoreClose

Focus on Health Equity

Tile-3
View More
Tile-3
View More
Tile-3
View More

Tile-4
View More

View More
View More
View MoreClose

Investigator Information and How to Contact Us

View More
View More
Tile-5
View MoreClose

Get it Done - Cancer Screening Campaign

View More
View More
View More
View More
View MoreClose

Pfizer Oncology Collaborating to Improve Patient Centricity

View More
View More
View More
View More

Commitment To Oncology

View More
View MoreClose

Supporting Our Patients

View More
View More

Scheduled Events

Symposium

Session Title: Is it time to raise the bar for ALK+ NSCLC Patients?
Location: Hall C2, Messe Wien Exhibition & Congress Center
Date and Time: August 6, 2022 14:30 - 15:30 CET

Add to Calendar


Poster Presentations

Presentation Title: Crizotinib in ROS1+ NSCLC: Long-term OS analysis in patients with brain metastases included in the phase II METROS trial
Location: All E-Posters will be displayed on a 60-inch digital screen on both days of the conference
Date and Time: August 7-8, 2022 09:45 – 18:00 CET

Add to Calendar

Presentation Title: Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Location: All E-Posters will be displayed on a 60-inch digital screen on both days of the conference
Date and Time: August 7-8, 2022 09:45 – 18:00 CET

Add to Calendar

Presentation Title: A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan Location: All E-Posters will be displayed on a 60-inch digital screen on both days of the conference
Date and Time: August 7-8, 2022 09:45 – 18:00 CET

Add to Calendar

Presentation Title: Lorlatinib for ALK+ NSCLC patients pretreated with second-generation ALK inhibitors: Canadian real-world experience
Location: All E-Posters will be displayed on a 60-inch digital screen on both days of the conference
Date and Time: August 7-8, 2022 09:45 – 18:00 CET

Add to Calendar


​​​​​​​Oral Presentations

Presentation Title: Avelumab vs Chemotherapy for First-Line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis From JAVELIN Lung 100
Location: Strauss 1/2
Date and Time: Tuesday, August 9, 2022 14:30 - 15:30 CET

Add to Calendar

Learn About Our Oncology Approved Medicines
​​​​​​​


LORVIQUA®
(lorlatinib)
SmPC (English)
SmPC (German)
LORVIQUA Website
(German)
 
View More

VIZIMPRO®
(dacomitinib)
SmPC (English)
SmPC (German)
VIZIMPRO Website
(German)
 
View More

XALKORI®
(crizotinib)
SmPC (English) 
SmPC (German) 
XALKORI Website
(German)
 
View More

X

PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.